Hunan Jiudian Pharmaceutical Co., Ltd., commonly referred to as Jiudian Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China. Established in 2001, the company has made significant strides in the development and production of high-quality pharmaceutical products, primarily focusing on innovative drug formulations and active pharmaceutical ingredients (APIs). With a strong operational presence across various regions in China, Jiudian Pharmaceutical is renowned for its commitment to research and development, which has led to the successful launch of several unique products. The company’s core offerings include a diverse range of prescription medications and over-the-counter solutions, distinguished by their efficacy and safety profiles. Recognised for its robust market position, Hunan Jiudian Pharmaceutical has achieved notable milestones, including certifications from international regulatory bodies, underscoring its dedication to quality and compliance in the pharmaceutical sector.
How does Hunan Jiudian Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hunan Jiudian Pharmaceutical Co., Ltd.'s score of 22 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hunan Jiudian Pharmaceutical Co., Ltd., headquartered in China, currently does not report any specific carbon emissions data, as indicated by the absence of figures in the latest emissions report. Consequently, there are no recorded emissions in terms of Scope 1, 2, or 3. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments towards reducing carbon emissions or addressing climate change. This absence of data and initiatives may reflect a broader industry context where pharmaceutical companies are increasingly expected to adopt sustainable practices and transparency in their environmental impact. As Hunan Jiudian Pharmaceutical Co., Ltd. does not inherit emissions data from a parent company or related organization, all information is based solely on their own reporting. The company may need to consider developing a comprehensive climate strategy to align with industry standards and stakeholder expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hunan Jiudian Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
